December 13, 2017 10:14am
FATE's public offering of 10,953,750 shares included 1,428,750 shares that were issued pursuant to the full exercise of the underwriters' option to purchase additional shares
Fate Therapeutics (FATE) has priced a share offering at $4.20 with an underwriting grant allotted of 1,428,750 shares to be sold
All shares of common stock to be sold in the offering will be offered by Fate Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Leerink Partners LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
After a good run in the last days … another jump through the capital access window …